Longer term For longer protocols, review metabolic, kidney, liver, and cardiovascular trends every 3-6 months with a clinician
The package arrived cold and the ice packs were still solid at delivery, but the outer shipping box was not insulated
Even after the FDA made clear that mass compounding of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) must stop, some compounders continue to manufacture and sell these unapproved products
That is the GLP-1 before and after story that thousands of people are living right now
We now have top line phase 3 data for retatrutide a triple (GIP, GLP-1, glucagon) agonist: At 40 weeks (efficacy estimand): ~16.8% weight loss ~1.9% A1c reduction We are entering a new phase: Multi-hormonal therapies Integrated obesity and diabetes care Precision approaches to cardiometabolic disease One pathway is not enough for a complex disease like obesity, and it is exciting to see a growing pipeline of therapies with distinct mechanisms